Failed Alzheimer's Disease Clinical Trials Analysis

Migration, Crosslink

📖

Failed Alzheimer's Disease Clinical Trials Analysis

active

wiki page Created: 2026-04-02T07:19:00 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-ad-failed-approaches-a

📖 Wiki Page

therapeutic1637 wordssynced 2026-04-02

Failed Alzheimer's Disease Clinical Trials Analysis

Overview

flowchart TD Failed_Alzheimer_s_Disease_Cli["Failed Alzheimers Disease Clinical Trials Analys"] Failed_Alzheimer_s_Disease_Cli["Alzheimer"] Failed_Alzheimer_s_Disease_Cli -->|"related to"| Failed_Alzheimer_s_Disease_Cli style Failed_Alzheimer_s_Disease_Cli fill:#81c784,stroke:#333,color:#000 Failed_Alzheimer_s_Disease_Cli["Trials"] Failed_Alzheimer_s_Disease_Cli -->|"related to"| Failed_Alzheimer_s_Disease_Cli style Failed_Alzheimer_s_Disease_Cli fill:#81c784,stroke:#333,color:#000 Failed_Alzheimer_s_Disease_Cli["table"] Failed_Alzheimer_s_Disease_Cli -->|"related to"| Failed_Alzheimer_s_Disease_Cli style Failed_Alzheimer_s_Disease_Cli fill:#81c784,stroke:#333,color:#000 style Failed_Alzheimer_s_Disease_Cli fill:#4fc3f7,stroke:#333,color:#000

...

Failed Alzheimer's Disease Clinical Trials Analysis

Overview

Mermaid diagram (expand to render)

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Failed Alzheimer's Disease Clinical Trials Analysis</th>
</tr>
<tr>
<td class="label">Trial</td>
<td>Drug</td>
</tr>
<tr>
<td class="label">EPOCH</td>
<td>Verubecestat</td>
</tr>
<tr>
<td class="label">MISSION-AD1</td>
<td>Atabecestat</td>
</tr>
<tr>
<td class="label">EANCEPT</td>
<td>Elenbecestat</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Drug</td>
</tr>
<tr>
<td class="label">IDENTITY</td>
<td>Semagacestat</td>
</tr>
<tr>
<td class="label">APOLLOE4</td>
<td>Avagacestat</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Drug</td>
</tr>
<tr>
<td class="label">AN-1792</td>
<td>Accumbens</td>
</tr>
<tr>
<td class="label">ACC-001</td>
<td>CAD106</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Drug</td>
</tr>
<tr>
<td class="label">EXPEDITION 1/2/3</td>
<td>Solanezumab</td>
</tr>
<tr>
<td class="label">[DIAN](/entities/dian-study)</td>
<td>Solanezumab</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Drug</td>
</tr>
<tr>
<td class="label">GRADUATE 1/2</td>
<td>Gantenerumab</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Drug</td>
</tr>
<tr>
<td class="label">EMERGE</td>
<td>Aducanumab</td>
</tr>
<tr>
<td class="label">ENGAGE</td>
<td>Aducanumab</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Drug</td>
</tr>
<tr>
<td class="label">CONCERT</td>
<td>Dimebolin</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Drug</td>
</tr>
<tr>
<td class="label">LIGHT</td>
<td>Azeliragon</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Drug</td>
</tr>
<tr>
<td class="label">TAURIEL</td>
<td>LMTM (TRx0237)</td>
</tr>
<tr>
<td class="label">Pattern</td>
<td>Example</td>
</tr>
<tr>
<td class="label">Wrong Abeta species</td>
<td>Solanezumab -> monomers</td>
</tr>
<tr>
<td class="label">Wrong pathway</td>
<td>[RAGE](/genes/rage) inhibitors</td>
</tr>
<tr>
<td class="label">Symptomatic only</td>
<td>Dimebolin</td>
</tr>
<tr>
<td class="label">Pattern</td>
<td>Example</td>
</tr>
<tr>
<td class="label">Poor brain penetration</td>
<td>Early antibodies</td>
</tr>
<tr>
<td class="label">Insufficient dosing</td>
<td>Early gantenerumab</td>
</tr>
<tr>
<td class="label">Pattern</td>
<td>Example</td>
</tr>
<tr>
<td class="label">Off-target toxicity</td>
<td>BACE, [gamma-secretase](/entities/gamma-secretase)</td>
</tr>
<tr>
<td class="label">Autoimmunity</td>
<td>AN-1792 vaccine</td>
</tr>
<tr>
<td class="label">Excessive caution</td>
<td>Underdosing</td>
</tr>
<tr>
<td class="label">Pattern</td>
<td>Example</td>
</tr>
<tr>
<td class="label">Too advanced</td>
<td>Most late-stage trials</td>
</tr>
<tr>
<td class="label">Mixed pathology</td>
<td>Including non-AD</td>
</tr>
<tr>
<td class="label">Biomarker-negative</td>
<td>No amyloid</td>
</tr>
</table>

This section provides an overview of Failed Alzheimer's Disease Clinical Trials Analysis. Additional content will be added here.

AD Failed Approaches Analysis

Introduction

Failed Alzheimer'S Disease Clinical Trials Analysis is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.

Executive Summary

Over 200 Alzheimer's disease clinical trials have failed over the past two decades. This page systematically analyzes these failures to identify patterns and extract actionable lessons for future therapeutic development.

Failed Trials: Detailed Analysis

BACE Inhibitors — Complete Failure

Failure Scores:

Was the target valid? 7/10 ([Aβ](/proteins/amyloid-beta) production reduction achieved)
Was the drug potent enough? 9/10 (significant Aβ reduction)
Did it reach the brain? 8/10 (good brain penetration)
Were patients too far gone? 3/10 (mild-to-moderate patients)
Was the trial designed well? 6/10

Key Lesson: BACE inhibition reduces Aβ but causes synaptic dysfunction. Need pathway modulation, not complete blockade.

Gamma-Secretase Inhibitors — Notch Toxicity

Failure Scores:

Was the target valid? 6/10 (reduces Aβ but not enough)
Was the drug potent enough? 8/10
Did it reach the brain? 8/10
Were patients too far gone? 4/10
Was the trial designed well? 5/10

Key Lesson: Broad-spectrum enzyme inhibition causes off-target toxicity. Need selective modulation.

Anti-Aβ Vaccines — Immune-Mediated Failure

Failure Scores:

Was the target valid? 8/10
Was the drug potent enough? 8/10
Did it reach the brain? 7/10 (antibodies crossed BBB)
Were patients too far gone? 4/10
Was the trial designed well? 5/10

Key Lesson: Active vaccination causes dangerous autoimmune response. Passive antibodies are safer.

Solanezumab — Wrong Target

Failure Scores:

Was the target valid? 4/10 (monomers not pathogenic)
Was the drug potent enough? 8/10
Did it reach the brain? 8/10
Were patients too far gone? 5/10 (some early patients)
Was the trial designed well? 7/10

Key Lesson: Must target the right toxic Aβ species (oligomers, protofibrils), not monomers.

Gantenerumab — Underdosing

Re-analysis Scores:

Was the target valid? 9/10
Was the drug potent enough? Initially 4/10, then 9/10
Did it reach the brain? 8/10
Were patients too far gone? 6/10
Was the trial designed well? 6/10

Key Lesson: Start with high doses in initial trials; don't undertreat for safety.

Aducanumab — Mixed Results

Analysis Scores:

Was the target valid? 9/10
Was the drug potent enough? 8/10
Did it reach the brain? 8/10
Were patients too far gone? 5/10
Was the trial designed well? 4/10 (stopped early, confounded)

Key Lesson: High-dose, continuous treatment essential; adaptive designs needed.

Dimebolin (Latrepirdine) — Inadequate Target Engagement

Failure Scores:

Was the target valid? 3/10 (mitochondrial, but unclear)
Was the drug potent enough? 4/10
Did it reach the brain? 7/10
Were patients too far gone? 4/10
Was the trial designed well? 6/10

RAGE Inhibitors — Wrong Mechanism

Failure Scores:

Was the target valid? 3/10
Was the drug potent enough? 7/10
Did it reach the brain? 6/10
Were patients too far gone? 4/10
Was the trial designed well? 7/10

Tau Aggregation Inhibitors — Modest Effect

Failure Scores:

Was the target valid? 7/10
Was the drug potent enough? 6/10
Did it reach the brain? 8/10
Were patients too far gone? 5/10
Was the trial designed well? 5/10

Key Lesson: [Tau](/proteins/tau) inhibitors may need combination with anti-amyloid.

Pattern Analysis: What the Failures Tell Us

1. Target Validity Issues (Score ≤4)

2. Delivery Issues (Score ≤4)

3. Safety Issues (Score ≤4)

4. Patient Selection Issues

What WILL Work: Evidence-Based Predictions

Based on failure analysis, the following approaches have highest probability of success:

Anti-Amyloid Antibodies (CONFIRMED)

[Lecanemab](/entities/lecanemab): Targets protofibrils, sufficient dosing, good safety[@van2023]
[Donanemab](/entities/donanemab): High-dose approach, plaque removal complete

Why they work: Learn from solanezumab (wrong target), gantenerumab (underdosing), BACE (off-target)

Combination Therapy (HIGH PROBABILITY)

Anti-amyloid + anti-[tau](/proteins/tau)
Anti-amyloid + GLP-1
Anti-amyloid + focused ultrasound

Why it works: Single targets have 27% ceiling; combinations address multiple pathways

Repurposed Drugs (MODERATE PROBABILITY)

GLP-1 agonists (semaglutide) — Good safety, multiple mechanisms
Masitinib — Positive Phase 3
Intranasal insulin — Good safety, direct delivery

Novel Mechanisms (EMERGING)

Anti-tau ASOs — Direct tau reduction
[TREM2](/proteins/trem2-protein) agonists — Microglial modulation
Gene therapy — Sustained delivery

Summary: Do's and Don'ts

✅ DO:

Target toxic Aβ species (protofibrils, oligomers)

Use high, continuous dosing from the start

Select patients with biomarker confirmation (amyloid+)

Treat early (preclinical or MCI due to AD)

Combine mechanisms (multi-target approach)

Include biomarker endpoints to verify target engagement

Design trials with sufficient power and duration

❌ DON'T:

Inhibit enzymes completely (BACE, gamma-secretase)

Target monomers or non-toxic Aβ forms

Underdose for safety concerns initially

Include biomarker-negative patients

Treat patients with moderate-to-severe dementia

Stop trials too early for futility

Ignore downstream effects (neurodegeneration)

Background

The study of Failed Alzheimer'S Disease Clinical Trials Analysis has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Cross-References

AD Therapeutic Approaches Scorecard — What works
AD Combination Therapy Matrix — Combination strategies
AD Knowledge Gaps Ranked — What we don't know
Tau Pathology — Tau mechanisms
Amyloid Hypothesis — Amyloid mechanisms

External Links

Additional resources and databases will be listed here.

References

[Egan MF, Kost J, Tariot PN, et al, Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29719179/)

[Doody RS, Raman R, Farlow M, et al, A phase 3 trial of semagacestat for treatment of Alzheimer's disease (2013)](https://pubmed.ncbi.nlm.nih.gov/23883379/)

[Orgogozo JM, Gilman S, Dartigues JF, et al, Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization (2003)](https://pubmed.ncbi.nlm.nih.gov/12847155/)

[Honig LS, Vellas B, Woodward M, et al, Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29365294/)

[Bateman RJ, Smith J, Donohue MC, et al, Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37966285/)

[Galasko DR, Bell J, Mancuso JY, et al, Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease (2014)](https://pubmed.ncbi.nlm.nih.gov/24696507/)

[Wilcock GK, Gauthier S, Frisoni GB, et al, Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial (2018)](https://pubmed.ncbi.nlm.nih.gov/27863809/)

[van Dyck CH, Swanson CJ, Aisen P, et al, Lecanemab in Early Alzheimer's Disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36449413/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — 0.77 · Target: SST
[Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — 0.73 · Target: BDNF
[ACSL4-Driven Ferroptotic Priming in Disease-Associated Microglia](/hypothesis/h-seaad-v4-26ba859b) — 0.73 · Target: ACSL4
[Prefrontal sensory gating circuit restoration via PV interneuron enhancement](/hypothesis/h-62f9fc90) — 0.72 · Target: PVALB
[Cell-Type Specific TREM2 Upregulation in DAM Microglia](/hypothesis/h-seaad-51323624) — 0.70 · Target: TREM2
[GFAP-Positive Reactive Astrocyte Subtype Delineation](/hypothesis/h-seaad-56fa6428) — 0.64 · Target: GFAP
[Excitatory Neuron Vulnerability via SLC17A7 Downregulation](/hypothesis/h-seaad-7f15df4c) — 0.63 · Target: SLC17A7
[SIRT3-Mediated Mitochondrial Deacetylation Failure with PINK1/Parkin Mitophagy Dysfunction](/hypothesis/h-seaad-v4-5a7a4079) — 0.62 · Target: SIRT3

Related Analyses:

[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[Tau propagation mechanisms and therapeutic interception points](/analysis/SDA-2026-04-02-gap-tau-prop-20260402003221) 🔄
[Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄
[Circuit-level neural dynamics in neurodegeneration](/analysis/SDA-2026-04-02-26abc5e5f9f2) 🔄
[SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-ad-failed-approaches-analysis

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-ad-failed-approaches-analysis
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-a8924462455d
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-ad-failed-approaches-analysis'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

233

Outgoing

258

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Failed Alzheimer's Disease Clinical Trials Analysis

Failed Alzheimer's Disease Clinical Trials Analysis

Overview

Failed Alzheimer's Disease Clinical Trials Analysis

Overview

AD Failed Approaches Analysis

Introduction

Executive Summary

Failed Trials: Detailed Analysis

BACE Inhibitors — Complete Failure

Gamma-Secretase Inhibitors — Notch Toxicity

Anti-Aβ Vaccines — Immune-Mediated Failure

Solanezumab — Wrong Target

Gantenerumab — Underdosing

Aducanumab — Mixed Results

Dimebolin (Latrepirdine) — Inadequate Target Engagement

RAGE Inhibitors — Wrong Mechanism

Tau Aggregation Inhibitors — Modest Effect

Pattern Analysis: What the Failures Tell Us

1. Target Validity Issues (Score ≤4)

2. Delivery Issues (Score ≤4)

3. Safety Issues (Score ≤4)

4. Patient Selection Issues

What WILL Work: Evidence-Based Predictions

Anti-Amyloid Antibodies (CONFIRMED)

Combination Therapy (HIGH PROBABILITY)

Repurposed Drugs (MODERATE PROBABILITY)

Novel Mechanisms (EMERGING)

Summary: Do's and Don'ts

✅ DO:

❌ DON'T:

Background

Cross-References

External Links

See Also

References

💬 Discussion

📗 Cite This Artifact

Failed Alzheimer's Disease Clinical Trials Analysis

Failed Alzheimer's Disease Clinical Trials Analysis

Overview

Failed Alzheimer's Disease Clinical Trials Analysis

Overview

AD Failed Approaches Analysis

Introduction

Executive Summary

Failed Trials: Detailed Analysis

BACE Inhibitors — Complete Failure

Gamma-Secretase Inhibitors — Notch Toxicity

Anti-Aβ Vaccines — Immune-Mediated Failure

Solanezumab — Wrong Target

Gantenerumab — Underdosing

Aducanumab — Mixed Results

Dimebolin (Latrepirdine) — Inadequate Target Engagement

RAGE Inhibitors — Wrong Mechanism

Tau Aggregation Inhibitors — Modest Effect

Pattern Analysis: What the Failures Tell Us

1. Target Validity Issues (Score ≤4)

2. Delivery Issues (Score ≤4)

3. Safety Issues (Score ≤4)

4. Patient Selection Issues

What WILL Work: Evidence-Based Predictions

Anti-Amyloid Antibodies (CONFIRMED)

Combination Therapy (HIGH PROBABILITY)

Repurposed Drugs (MODERATE PROBABILITY)

Novel Mechanisms (EMERGING)

Summary: Do's and Don'ts

✅ DO:

❌ DON'T:

Background

Cross-References

External Links

See Also

References

Related Hypotheses

💬 Discussion